<DOC>
	<DOCNO>NCT00063609</DOCNO>
	<brief_summary>The purpose study compare effect investigational drug use intravenously placebo administer every three month one year , bone loss associate initial androgen deprivation ) men prostate cancer without metastasis . In order participate trial male patient must 18 year age old diagnosed prostate cancer without metastasis within one year start androgen deprivation therapy day randomization onto trial . In addition , patient undergone recent orchiectomy ( '' ke-ek'te-me ) ( removal one two testis ) eligible participate . Patients receive prior bisphosphonate therapy prior treatment systemic corticosteroid within past 12 month eligible participate . Also patient receive treatment osteoporosis eligible participate . Inclusion clinical trial investigational drug base protocol entry criterion evaluation participate trial investigator .</brief_summary>
	<brief_title>The Effect Zoledronic Acid Bone Loss Prostate Cancer Patients Undergoing Androgen Deprivation Therapy</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>Histologically confirm diagnosis carcinoma prostate No distant metastasis ( stage TNMO ) ( ie . prostate cancer without metastasis ) Patients within one year day randomization initiation androgen deprivation therapy LHRH agonist ( without antiandrogen ) intend duration androgen deprivation therapy least 12 month . Patients may also enter receive orchiectomy ( '' keek'teme ) within two week visit 1 Patients receive prior bisphosphonate therapy past 12 month exclude Patients currently receive diethylstilbesterol ( DES ) PCSPES ( treatment osteoporosis ) exclude Patients receive prior treatment systemic corticosteroid within past 12 month exclude ( short term corticosteroid therapy , e.g . prevent/treat chemotherapyinduced nausea/vomiting acute illness like asthma exacerbation , acceptable ) Other eligibility criterion may apply</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>Prostate Cancer</keyword>
	<keyword>Bone Loss</keyword>
	<keyword>Osteoporosis</keyword>
	<keyword>Bone Mineral Density</keyword>
	<keyword>Androgen Deprivation Therapy</keyword>
</DOC>